• Amarin’s (NASDAQ:AMRN) share prices sky rocketed 95% after promising results from a new cholesterol drug led to speculation that the company could soon be a takeover target for Big Pharma • Share prices of Marvell (NASDAQ:MRVL) dropped 4.57% after Susquehanna downgraded the stock to “Neutral” from “Positive” and slashed the target price to $17 from $23 [...] (AMRN) Company News for April 19, 2011 – Corporate Summary